US2022054457A2PendingUtilityA2

Methods for treating ocular demodex using spinosad formulations

Assignee: TARSUS PHARMACEUTICALS INCPriority: Dec 15, 2017Filed: Nov 16, 2020Published: Feb 24, 2022
Est. expiryDec 15, 2037(~11.4 yrs left)· nominal 20-yr term from priority
A61P 17/00A61K 31/155A61P 27/02A61P 33/14A61K 47/26A61K 9/0048A61K 9/08A61K 31/422A61K 31/42
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 20 . (canceled) 
     
     
         21 . A method for treating an ocular  Demodex  mite infestation, comprising: topically administering to one or more of the eye, eyelid, or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad. 
     
     
         22 . The method of  claim 21 , wherein the composition comprises an eye drop. 
     
     
         23 . The method of  claim 21 , wherein the composition comprises an ointment. 
     
     
         24 . The method of  claim 21 , wherein the composition comprises a cream. 
     
     
         25 . The method of  claim 21 , wherein the composition comprises an emulsion. 
     
     
         26 . The method of  claim 21 , wherein the composition comprises a suspension. 
     
     
         27 . The method of  claim 21 , wherein the  Demodex  mite comprises one or more of  Demodex folliculorum  and  Demodex brevis.    
     
     
         28 . The method of  claim 21 , wherein the composition further comprises an isoxazoline parasiticide. 
     
     
         29 . The method of  claim 28 , wherein the isoxazoline parasiticide comprises lotilaner. 
     
     
         30 . The method of  claim 21 , wherein the composition further comprises tea tree oil. 
     
     
         31 . The method of  claim 21 , wherein the ocular  Demodex  mite infestation comprises blepharitis. 
     
     
         32 . The method of  claim 21 , wherein the ocular  Demodex  mite infestation comprises meibomian gland dysfunction. 
     
     
         33 . The method of  claim 21 , wherein the ocular  Demodex  mite infestation comprises ocular rosacea. 
     
     
         34 . The method of  claim 21 , wherein the composition further comprises an antibiotic agent. 
     
     
         35 . The method of  claim 21 , further comprising confirming the presence of  Demodex  mites prior to the topically administering. 
     
     
         36 . The method of  claim 21 , wherein confirming the presence of  Demodex  mites comprises identifying cylindrical dandruff, identifying  Demodex  mites, or testing for the presence of a biomarker associated with  Demodex  mites. 
     
     
         37 . The method of  claim 21 , wherein the composition comprises an additional agent having miticidal activity against the  Demodex  mite. 
     
     
         38 . The method of  claim 21 , wherein the additional agent is selected from the group consisting of: ivermectin, moxidectin, metronidazole, and amitraz. 
     
     
         39 . A method for treating an ocular  Demodex  mite infestation, comprising: topically administering to one or more of the eyelid or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad. 
     
     
         40 . A method for treating  Demodex  blepharitis, comprising: topically administering to one or more of the eyelid or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad.

Join the waitlist — get patent alerts

Track US2022054457A2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.